PERIPHERAL T-CELL LYMPHOMA
Clinical trials for PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested an experimental drug called AZD4205 in 57 adults with a rare type of blood cancer (peripheral T-cell lymphoma) that had returned or stopped responding to prior therapy. The goal was to see if the drug could shrink tumors and how safe it was. Participants took a …
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New drug cocktail shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a combination of four drugs (romidepsin, CC-486, dexamethasone, and lenalidomide) in 26 adults with T-cell cancers that had come back or stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Rese…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New drug shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study had two parts: one to determine t…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
Immunotherapy after transplant shows promise for lymphoma control
Disease control CompletedThis study tested whether giving the immunotherapy drug pembrolizumab after a stem cell transplant could help keep lymphoma from coming back. It included 82 adults with Hodgkin or non-Hodgkin lymphoma that had returned or not responded to prior treatment. The main goal was to see…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for rare blood cancer: targeted therapy plus chemo shows promise
Disease control CompletedThis study tested a combination of the targeted drug brentuximab vedotin plus standard chemotherapy (CHP) in 82 people with a rare type of lymphoma called peripheral T-cell lymphoma (PTCL) that has low levels of a protein called CD30. The goal was to see how well the treatment sh…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Experimental combo aims to boost stem cell transplant success for rare blood cancers
Disease control CompletedThis early-phase study tested whether adding the drug romidepsin to standard chemotherapy before and after a stem cell transplant could help control T-cell cancers like lymphoma and leukemia. Researchers enrolled 23 adults to find the safest dose and see if the combination helped…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:52 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of two drugs, nivolumab and cabiralizumab, in 4 adults with a rare and aggressive blood cancer called peripheral T-cell lymphoma that had come back or stopped responding to treatment. The goal was to see if the drug pair could shrink tumors. The tr…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New combo therapy for lymphoma shows promise in early trial
Disease control CompletedThis early-phase study tested a new combination of drugs (romidepsin plus standard chemotherapy) in 21 patients with peripheral T-cell or diffuse large B-cell lymphoma. The main goal was to find the safest dose and understand side effects. Researchers hope this combo might work b…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug shows promise for Hard-to-Treat cancers with p53 gene
Disease control CompletedThis study tested a new drug, ALRN-6924, in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments. The study found the dru…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Aileron Therapeutics, Inc. • Aim: Disease control
Last updated May 04, 2026 16:29 UTC